Standout Papers
- Ovarian cancer (2014)
- Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer (2012)
- Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial (2014)
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial (2003)
- Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2013)
- ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer (2015)
- Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial (2013)
- Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial (2017)
- Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial (2016)
- Endometrial cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer (2020)
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease (2019)
- Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial (2021)
- Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
Immediate Impact
2 by Nobel laureates 11 from Science/Nature 90 standout
Citing Papers
Luminescent Lanthanides in Biorelated Applications: From Molecules to Nanoparticles and Diagnostic Probes to Therapeutics
2025 Standout
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
Works of Jonathan A. Ledermann being referenced
Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments
2015
Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells
2006
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Jonathan A. Ledermann | 7733 | 8893 | 2059 | 4841 | 277 | 16.8k | |
| Gini F. Fleming | 5227 | 7997 | 1671 | 4050 | 326 | 16.2k | |
| Carol Aghajanian | 7236 | 5973 | 840 | 3577 | 408 | 14.8k | |
| Nicoletta Colombo | 10071 | 6873 | 1278 | 3175 | 408 | 17.3k | |
| Ana Oaknin | 4106 | 6468 | 1143 | 3616 | 292 | 11.9k | |
| Ursula A. Matulonis | 8004 | 13055 | 2627 | 7706 | 424 | 22.4k | |
| Andrew Berchuck | 6748 | 5699 | 2848 | 8006 | 353 | 19.5k | |
| Robert A. Burger | 8870 | 4510 | 1000 | 3506 | 200 | 14.4k | |
| Gordon Rustin | 5054 | 5247 | 1174 | 3993 | 244 | 15.7k | |
| Gunnar B. Kristensen | 7386 | 4200 | 811 | 3491 | 257 | 14.3k | |
| Karen H. Lu | 8090 | 6678 | 3842 | 7308 | 425 | 21.0k |
All Works
Login with ORCID to disown or claim papers
Loading papers...